Valuation : Incyte Corporation

Market Cap 25.22B 21.7B 20.43B 18.62B 34.83B 2,399B 34.97B 242B 93.59B 1,222B 94.68B 92.63B 3,873B P/E 2026 *
55.5x
P/E 2027 * 17.2x
Enterprise Value 20.99B 18.06B 17B 15.49B 28.99B 1,997B 29.1B 202B 77.89B 1,017B 78.8B 77.09B 3,223B EV / Sales 2026 *
3.53x
EV / Sales 2027 * 3.07x
Free-Float
98.16%
Yield 2026 *
-
Yield 2027 * -
1 day+0.30%
1 week-0.56%
Current month-0.14%
1 month+2.26%
3 months+22.04%
6 months+29.73%
Current year+26.61%
1 week 106.25
Extreme 106.25
110.15
1 month 103.3
Extreme 103.3
110.75
Current year 77.6
Extreme 77.6
115.4
1 year 69.58
Extreme 69.58
115.4
3 years 47.11
Extreme 47.11
115.4
5 years 47.11
Extreme 47.11
115.4
10 years 47.11
Extreme 47.11
144.13
Manager TitleAgeSince
Chief Executive Officer 58 2025-06-25
Director of Finance/CFO 57 2026-05-03
President 62 2023-06-04
Director TitleAgeSince
Chairman 59 2025-06-25
Director/Board Member 72 2015-01-19
Director/Board Member 64 2015-01-19
Change 5-day change 1-year change 3-year change Capi.($)
+0.30%-0.56% - - 25.22B
-0.80%-5.73%+44.33%-3.63% 80.91B
-0.78%-0.64%-19.76%-36.79% 60.46B
-2.14%-8.88%+461.57%+29.88% 56.02B
+0.83%-4.47%-8.40%+30.44% 49.63B
-1.11%-7.21%-2.15%+148.24% 45.88B
-0.41%-4.89%+47.49%-18.20% 31.4B
+1.50%-1.84%+47.73%+96.34% 25.22B
-2.00%-3.35%-2.29%+177.79% 22.25B
-3.02%-2.59%+60.23%+99.82% 16.59B
Average -0.75%-1.29%+69.86%+58.21% 43.15B
Weighted average by Cap. -0.72%-1.13%+80.80%+38.46%

Financials

2026 *2027 *
Net sales 5.94B 5.11B 4.81B 4.39B 8.21B 565B 8.24B 57.06B 22.05B 288B 22.31B 21.83B 913B 6.27B 5.39B 5.08B 4.63B 8.65B 596B 8.69B 60.16B 23.25B 304B 23.53B 23.01B 962B
Net income 466M 401M 377M 344M 643M 44.33B 646M 4.47B 1.73B 22.58B 1.75B 1.71B 71.54B 1.5B 1.29B 1.21B 1.1B 2.07B 142B 2.07B 14.36B 5.55B 72.52B 5.62B 5.49B 230B
Net Debt -4.23B -3.64B -3.43B -3.12B -5.84B -402B -5.87B -40.62B -15.7B -205B -15.88B -15.54B -650B -5.99B -5.16B -4.85B -4.42B -8.28B -570B -8.31B -57.53B -22.23B -290B -22.5B -22.01B -920B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
26-09-09 106.25 -1.80% 0
26-09-08 €108.20 -1.46% 0
26-09-07 €109.80 +0.32% 0
26-09-04 €109.45 -0.41% 0
26-09-03 €109.90 +2.85% 25
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
124.40USD
Average target price
127.74USD
Spread / Average Target
+2.68%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!